Modalis Therapeutics Corporation (4883.T)
- Previous Close
81.00 - Open
79.00 - Bid 79.00 x --
- Ask 80.00 x --
- Day's Range
78.00 - 81.00 - 52 Week Range
62.00 - 203.00 - Volume
648,300 - Avg. Volume
2,518,761 - Market Cap (intraday)
5.884B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-28.57 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
modalistx.com14
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4883.T
View MorePerformance Overview: 4883.T
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4883.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4883.T
View MoreValuation Measures
Market Cap
5.96B
Enterprise Value
2.38B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.24%
Return on Equity (ttm)
-53.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.32B
Diluted EPS (ttm)
-28.57
Balance Sheet and Cash Flow
Total Cash (mrq)
3.58B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-890.63M